Igm Biosciences Inc (IGMS) Stock Price, Quote & News

Company Profile

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 965 7873

Website: igmbio.com

Address:

325 East Middlefield Road, Mountain View, United States

TheRealShortSqueezy Dec. 15 at 3:26 PM

$HYFT: Riding the AI Biotech Wave Into Its Next Stage of Growth With AI fueling a new era of biotech breakthroughs, MindWalk is perfectly positioned, merging deep tech and biology to accelerate discoveries the entire sector has been waiting for. 📞 Conference Call Coming Up As the call approaches, investors are looking for clarity on HYFT’s accelerating momentum. Key topics expected to be discussed include: ➖ Record Q2 revenue growth and margin expansion ➖ Updates on the GLP-1 + longevity programs and dengue vaccine progress ➖ Strategic direction heading into the mid-January JPM update 💰 Strengthened by September’s Strategic Move On Sept 15, MindWalk sold its Netherlands operations, unlocking over $14M. That capital is now being directed into HYFT’s core BioNative AI platform and wet lab programs. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $FATE $IGMS $ANTX $CABA

1 · Reply

TheRealShortSqueezy Dec. 15 at 1:47 PM

$HYFT: RECORD Growth + Big Pipeline Wins Just Dropped 🗞️📰 MindWalk Holdings Corp just delivered its strongest quarter yet, combining major financial momentum with breakthrough AI driven pipeline progress. 📈 Financial Highlights: ➖ Revenue $4.1M (+54% YoY, +30% QoQ) ➖Gross margin 65% (up from 51%) ➖Gross profit +94% YoY ➖ $16.5M cash for platform + pipeline expansion 🧬 Pipeline Highlights: ➖ GLP-1: AI-designed agonist outperforming semaglutide ➖ Added longevity pathway → dual-pathway metabolic program 💥 Strategic Progress: ➖ Rebrand completed + new CFO/CBO ➖ Netherlands sale → $14.3M redirected to AI + wet lab programs 🔥 Next Catalyst: ➖ Mid-January pipeline + partnership update at JPM Healthcare Conference Record growth, stronger margins, and a loaded pipeline, $HYFT’s momentum is accelerating fast. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $IGMS $ANTX $CABA $ENTX

0 · Reply

smartkarma Oct. 26 at 8:15 PM

$IGMS | Primer: IGM Biosciences Inc (IGMS US) - Oct 2025 "IGM Biosciences is a clinical-stage biotechnology company centered on a proprietary platform for developing engineered Immunoglobulin M (IgM)..." - αSK (Smartkarma) Read more: https://www.smartkarma.com/insights/primer-igm-biosciences-inc-igms-us-oct-2025

0 · Reply

FadeSignal Sep. 15 at 10:14 AM

$IGMS Leverage to AI/cloud trends; adoption pace will dictate returns

0 · Reply

paulosous Sep. 11 at 10:22 AM

$IGMS I loose all my shares, receiving only the CVR its normal?

0 · Reply

FreeBeerTomorrow Aug. 14 at 7:48 AM

$IGMS IGM Biosciences (IGMS) stock has been halted in anticipation of a merger with Concentra Biosciences. The tender offer for the acquisition is set to expire, and the merger is expected to close soon. Trading was halted at the end of the after-hours session on August 13, 2025, and will remain halted on August 14, 2025, with the stock being suspended from trading effective August 15, 2025.

0 · Reply

Mergerbrief Aug. 13 at 12:10 PM

$IGMS / Concentra Biosciences - Tender Offer Expires MergerBrief.com For Full Schedule Of Events

0 · Reply

TwongStocks Aug. 12 at 7:56 PM

$IGMS NASDAQ Equity Corporate Actions Alert # 2025 - 436 Information Regarding the Tender Offer of IGM Biosciences, Inc. (IGMS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-436 The tender offer by Concentra Biosciences to acquire all of the outstanding common stock of IGM Biosciences, Inc. (IGMS) is scheduled to expire one minute after 11:59 p.m. ET on August 13, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on August 14, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on August 13, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (August 14) and will be suspended effective August 15, 2025. Tender offer: $1.247 for each IGMS share held plus one non-tradeable contingent value right (CVR).

0 · Reply

EquityInvest Aug. 6 at 6:39 PM

$IGMS I was yelling short this when it was a high flyer two years ago - the CEO it was clear that this thing was going to a dollar. He’s just lucky to not be sued for incompetence.

0 · Reply

sumon89 Jul. 30 at 4:31 PM

$IGMS when will the deal be concluded!?

0 · Reply

IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right

Jan 9, 2025, 2:27 PM EST - 1 year ago

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

Jan 9, 2025, 1:00 PM EST - 1 year ago

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

Nov 8, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 7:00 AM EST - 1 year ago

IGM Biosciences to Present at Three Upcoming Investor Conferences

Oct 1, 2024, 11:41 AM EDT - 1 year ago

IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay

Oct 1, 2024, 11:40 AM EDT - 1 year ago

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

Oct 1, 2024, 8:00 AM EDT - 1 year ago

IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases

Oct 1, 2024, 7:54 AM EDT - 1 year ago

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Sep 30, 2024, 4:01 PM EDT - 1 year ago

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

Sep 10, 2024, 4:05 PM EDT - 1 year ago

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 14, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Jefferies Healthcare Conference

May 8, 2024, 4:10 PM EDT - 1 year ago

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

Apr 17, 2024, 8:30 AM EDT - 1 year ago

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Apr 10, 2024, 7:00 AM EDT - 1 year ago

IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Mar 7, 2024, 4:10 PM EST - 1 year ago

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 12, 2024, 3:09 PM EST - 2 years ago

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Feb 1, 2024, 7:00 AM EST - 2 years ago

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 6, 2023, 2:44 AM EST - 2 years ago

Medivir to present at the Carlsquare Equity Research Investor Day

Dec 5, 2023, 4:01 PM EST - 2 years ago

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Dec 1, 2023, 5:32 AM EST - 2 years ago

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Nov 27, 2023, 3:52 AM EST - 2 years ago

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Nov 22, 2023, 2:46 AM EST - 2 years ago

Medivir to present at the Redeye Life Science Day

Nov 21, 2023, 2:48 AM EST - 2 years ago

Medivir to present at the Erik Penser Bank Company Event

Nov 13, 2023, 4:10 PM EST - 2 years ago

IGM Biosciences Announces Third Quarter 2023 Financial Results

Nov 13, 2023, 3:49 AM EST - 2 years ago

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Nov 7, 2023, 7:00 AM EST - 2 years ago

IGM Biosciences to Present at Two Upcoming Investor Conferences

Oct 25, 2023, 2:46 AM EDT - 2 years ago

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Oct 23, 2023, 2:48 AM EDT - 2 years ago

Nomination Committee of Medivir appointed

Oct 20, 2023, 9:29 AM EDT - 2 years ago

Change in Medivir's Board of Directors

Oct 5, 2023, 7:29 AM EDT - 2 years ago

Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

Oct 3, 2023, 4:05 PM EDT - 2 years ago

IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z.

Sep 11, 2023, 5:41 AM EDT - 2 years ago

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Sep 7, 2023, 3:46 AM EDT - 2 years ago

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

Sep 6, 2023, 7:00 AM EDT - 2 years ago

IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 4, 2023, 2:52 AM EDT - 2 years ago

Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

Sep 1, 2023, 3:20 AM EDT - 2 years ago

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Aug 14, 2023, 3:03 AM EDT - 2 years ago

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Aug 7, 2023, 2:46 AM EDT - 2 years ago

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Aug 3, 2023, 4:10 PM EDT - 2 years ago

IGM Biosciences Announces Second Quarter 2023 Financial Results

Jul 3, 2023, 4:01 PM EDT - 2 years ago

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 22, 2023, 7:58 AM EDT - 2 years ago

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

Jun 21, 2023, 5:17 PM EDT - 2 years ago

IGM Announces Proposed Public Offering and Concurrent Private Placement

Jun 19, 2023, 4:12 AM EDT - 2 years ago

Medivir's patent application for fostrox approved in China

TheRealShortSqueezy Dec. 15 at 3:26 PM

1 · Reply

TheRealShortSqueezy Dec. 15 at 1:47 PM

0 · Reply

smartkarma Oct. 26 at 8:15 PM

0 · Reply

FadeSignal Sep. 15 at 10:14 AM

$IGMS Leverage to AI/cloud trends; adoption pace will dictate returns

0 · Reply

paulosous Sep. 11 at 10:22 AM

$IGMS I loose all my shares, receiving only the CVR its normal?

0 · Reply

FreeBeerTomorrow Aug. 14 at 7:48 AM

0 · Reply

Mergerbrief Aug. 13 at 12:10 PM

$IGMS / Concentra Biosciences - Tender Offer Expires MergerBrief.com For Full Schedule Of Events

0 · Reply

TwongStocks Aug. 12 at 7:56 PM

0 · Reply

EquityInvest Aug. 6 at 6:39 PM

$IGMS I was yelling short this when it was a high flyer two years ago - the CEO it was clear that this thing was going to a dollar. He’s just lucky to not be sued for incompetence.

0 · Reply

sumon89 Jul. 30 at 4:31 PM

$IGMS when will the deal be concluded!?

0 · Reply

NVDAMillionaire Jul. 28 at 10:57 PM

$IGMS Really good write-up that perfectly summarizes IGMS's present situation. So if you want to bring your IGMS knowledge up to date or just discover IGMS, this is required reading. https://beyondspx.com/article/igm-biosciences-a-strategic-pivot-culminates-in-acquisition-valuing-cash-and-contingent-upside-igms

1 · Reply

Candy_Wife Jul. 16 at 11:07 PM

$IGMS Did the reverse split already happen? Can't find anything about it online.

0 · Reply

sumon89 Jul. 10 at 8:30 AM

$IGMS 1.so we will lose ownership of the shares we have on this stock ? 2. the share holders are obligated to agree with the price or cand they keep the shares of igms till they become shares of the new company? Cand anyone help me understand!?

1 · Reply

SumDay1Day Jul. 1 at 8:04 PM

$IGMS What do we have here? I will toss in for 1000 shares to keep an eye on it.

0 · Reply

prismmarketview Jul. 1 at 3:25 PM

$IGMS Biotech M&A Alert: IGM Biosciences (NASDAQ: $IGMS) is being acquired by Concentra Biosciences in a cash + CVR deal that could unlock even more value for shareholders. Stock is up 18% as the market reacts. Deal expected to close by August!

0 · Reply

Blackcoupe369 Jul. 1 at 2:02 PM

$IGMS looks like she has more

0 · Reply

kebrik Jul. 1 at 1:55 PM

Today's movers: $IGMS, $WETO, $LIXT, $GPUS, and $ARBK

0 · Reply

Crapmaster2000 Jul. 1 at 1:39 PM

$IGMS 1.24 is not what I was hoping for on this deal, I was looking for at least 2.00/

0 · Reply

DARKP00L Jul. 1 at 1:33 PM

$IGMS 09:25 on Jul. 01 2025 IGM Biosciences shares are trading higher after the company announced it will be acquired by Concentra Biosciences for $1.247 per share. #tradeideas

0 · Reply

Stock_Catcher Jul. 1 at 1:33 PM

$IGMS technical set up

0 · Reply

DARKP00L Jul. 1 at 1:25 PM

$IGMS 09:25 on Jul. 01 2025 IGM Biosciences shares are trading higher after the company announced it will be acquired by Concentra Biosciences for $1.247 per share. #tradeideas

0 · Reply

patb99 Jul. 1 at 1:03 PM

$IGMS wait the drop

0 · Reply

Market Cap	76.57M
Revenue (ttm)	2.68M
Net Income (ttm)	-195.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,305.97%
Debt to Equity Ratio	0.00

Volume	1,618,900
Avg Vol	740,806
Day's Range	N/A - N/A
Shares Out	60.29M
Stochastic %K	25%
Beta	0.60
Analysts	Hold
Price Target	$1.41